Catalyst Pharmaceuticals (CPRX) Revenue (2018 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Revenue came in at $149.4 million in Q1 2026, up 5.63% YoY from $141.4 million in Q1 2025, and down 2.11% on a QoQ basis from $152.6 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Revenue (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 9 years of Revenue data on file, last reported at $149.4 million in Q1 2026.
- Quarterly Revenue rose 5.63% year-over-year to $149.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $597.0 million (up 11.65% YoY) and the FY2025 annual result came in at $589.0 million, up 19.78% from the prior year.
- Revenue declined to $149.4 million in Q1 2026, from $152.6 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $152.6 million in Q4 2025 to a low of $43.1 million in Q1 2022.
- A 5-year average of $108.4 million and a median of $110.6 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue jumped 98.12% — and 2026, when it climbed 5.63%.
- Tracing CPRX's Revenue over 5 years: stood at $60.8 million in 2022, then soared by 81.98% to $110.6 million in 2023, then climbed by 28.26% to $141.8 million in 2024, then increased by 7.61% to $152.6 million in 2025, then slipped by 2.11% to $149.4 million in 2026.
- The last three Revenue figures came in at $149.4 million (Q1 2026), $152.6 million (Q4 2025), and $148.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 149.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149.39 Mn |
| Dec 31, 2025 | 152.61 Mn |
| Sep 30, 2025 | 148.39 Mn |
| Jun 30, 2025 | 146.56 Mn |
| Mar 31, 2025 | 141.42 Mn |
| Dec 31, 2024 | 141.82 Mn |
| Sep 30, 2024 | 128.70 Mn |
| Jun 30, 2024 | 122.71 Mn |
| Mar 31, 2024 | 98.51 Mn |
| Dec 31, 2023 | 110.57 Mn |
| Sep 30, 2023 | 102.69 Mn |
| Jun 30, 2023 | 99.58 Mn |
| Mar 31, 2023 | 85.37 Mn |
| Dec 31, 2022 | 60.76 Mn |
| Sep 30, 2022 | 57.24 Mn |
| Jun 30, 2022 | 53.11 Mn |
| Mar 31, 2022 | 43.09 Mn |
| Dec 31, 2021 | 38.31 Mn |
| Sep 30, 2021 | 35.95 Mn |
| Jun 30, 2021 | 36.37 Mn |